No, Wegovy Does Not Have an SNAC Coating
Wegovy (subcutaneous semaglutide) does not contain SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate). SNAC is an absorption enhancer used exclusively in the oral formulation of semaglutide (Rybelsus), not in the injectable formulation marketed as Wegovy 1.
Key Distinctions Between Formulations
Wegovy (Subcutaneous Semaglutide)
- Route: Once-weekly subcutaneous injection
- Bioavailability: ~89% 2
- Composition: Contains only semaglutide with inactive ingredients (disodium phosphate dihydrate, sodium chloride, water for injection) 1
- No SNAC required: The injectable route bypasses gastrointestinal barriers, allowing direct systemic absorption
Rybelsus (Oral Semaglutide)
- Route: Daily oral tablet
- Bioavailability: ~1% (requires SNAC) 2
- Composition: Co-formulated with SNAC absorption enhancer 3, 4
- SNAC function: Prevents gastric degradation and facilitates transcellular absorption through the gastric epithelium in a concentration-dependent manner 3, 4
Why SNAC Is Necessary for Oral—But Not Injectable—Semaglutide
Semaglutide is a peptide that would normally be destroyed by gastric acid and digestive enzymes if taken orally. SNAC creates a localized pH increase in the stomach that protects semaglutide and enhances its absorption across the gastric membrane 4. This technology enables oral delivery but is completely unnecessary for subcutaneous administration, where the drug enters systemic circulation directly.
Clinical Implications
Both formulations demonstrate comparable efficacy:
- Wegovy (subcutaneous 2.4 mg weekly): 14.9-16.9% weight reduction 5
- Oral semaglutide (50 mg daily): 15.1-17.1% weight reduction 5, 2
The choice between formulations depends on patient preference (needle-averse individuals may prefer oral), adherence patterns, and cost considerations—not on the presence or absence of SNAC, which is purely a pharmaceutical necessity for oral bioavailability 2, 6.